Release Date: December 18, 2025

Expiration Date: January 15, 2026

Activity Overview

This educational activity is an archive of the live presentation held on Monday, December 8, 2025.

For more information about this educational activity, the faculty, and disclosures, please click here.

Target Audience

This educational activity is directed toward medical oncologists, advanced practice providers, nurses, and other health care professionals involved in the treatment and management of metastatic breast cancer.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

Interpret recent clinical trial data evaluating new therapies and novel combinations for the treatment of HR+/HER2- metastatic breast cancer (MBC)
Develop individualized treatment plans that utilize targeted therapies for patients with endocrine-sensitive HR+/HER2- MBC
Incorporate the best available evidence to select and sequence antibody-drug conjugates for the treatment of endocrine-resistant HR+/HER2-low MBC
Implement strategies to manage treatment-related adverse events and support adherence through patient education and shared decision-making

Medical Crossfire®: From Frontline to Heavily Pretreated HR+/HER2- Metastatic Breast Cancer: Expert Perspectives on Optimizing the Expanding Treatment Armamentarium

GET STARTED WITH THIS PROGRAM:

Create Account Already Registered? Login Here

Accreditation/Credit Designation

Physicians’ Education Resource^®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource^®, LLC designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource^®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 2.0 Contact Hours.

Acknowledgment of Commercial Support

This activity is supported by educational grants from AstraZeneca; BioNTech; Genentech, Inc; and Stemline Therapeutics, Inc.

Medical Crossfire®: From Frontline to Heavily Pretreated HR+/HER2- Metastatic Breast Cancer: Expert Perspectives on Optimizing the Expanding Treatment Armamentarium

GET STARTED WITH THIS PROGRAM:

Related Content